The FINANCIAL -- The World Health Organization (WHO) listed the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson & Johnson), for emergency use in all countries and for COVAX roll-out. The decision comes on the back of the European Medicines Agency (EMA) authorization, which was announced two days ago according to WHO.…
Read More »
The FINANCIAL -- The World Health Organization (WHO) listed the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson & Johnson), for emergency use in all countries and for COVAX roll-out. The decision comes on the back of the European Medicines Agency (EMA) authorization, which was announced two days ago according to WHO.…
You might be interested in
The FINANCIAL — People with certain inflammatory immune conditions affecting the joints, bowel and skin, such as rheumatoid arthritis, may have…
Epidemiologist explains how to stay on guard against subvariants, noting role of protective measures in transition to new pandemic phase…
A new study measuring the impact of COVID-19 on the wellbeing and mental health of adolescents has found that the…